Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma

Summary

The goal of this study is to find the highest tolerated dose of NC-6300 that can be given to patients with advanced solid tumors or soft tissue sarcoma. The safety and tolerability of the drug will also be studied.

Timeline

Start

2017-06-30

Primary completion

2020-07

Completion

2020-07

Publications

• Riedel RF, Chua V, Moradkhani A, Krkyan N, Ahari A, Osada A, Chawla SP. Results of NC-6300 (Nanoparticle Epirubicin) in an Expansion Cohort of Patients with Angiosarcoma. Oncologist. 2022 Oct 1;27(10):809-e765. doi: 10.1093/oncolo/oyac155.

Drugs

Indications